Mounjaro weight loss injections 5mg: the evidence behind the first therapeutic dose

What the trial data tell us about the 5mg stage of treatment

SURMOUNT-1 enrolled 2,539 adults with obesity and no diabetes over 72 weeks. Participants didn't start at a high dose; the protocol stepped everyone up gradually, spending time at each dose level before moving to the next. That design was deliberate. The titration exists partly so the gastrointestinal system can adjust, nausea and related symptoms are most common at the start of treatment or after a dose increase, and a slower climb reduces their impact. By the time participants in the trial reached maintenance doses of 10mg or 15mg, the 5mg stage was already behind them, having done its job.

NICE's appraisal of tirzepatide (TA1026, updated September 2025) references the full titration schedule as part of what makes the medicine clinically appropriate for adults with a BMI of 35 or above alongside at least one weight-related condition. The 5mg dose is not a lesser version of the treatment; it is the foundation the higher doses stand on.

For people transferring from another provider already at 5mg, the clinical picture at that point matters just as much as the starting point. Evidence of current treatment and weight are reviewed before any repeat is issued, that applies to the full tirzepatide dosage pathway at every step, not just the first.

Side effects at 5mg: what tends to happen and when

The side-effect profile at 5mg is consistent with what the SmPC and NHS guidance describe for tirzepatide generally: nausea, loose stools, constipation, indigestion, burping and fatigue are the most commonly reported. The practical reality is that these tend to be most noticeable in the first week or two after a dose change, then settle for most people as the body adjusts.

One signal that deserves specific mention: the MHRA issued a Drug Safety Update in January 2026 flagging acute pancreatitis as a known but infrequent side effect of GLP-1 class medicines. Severe stomach pain that radiates towards the back (with or without vomiting) is a reason to seek urgent medical attention. This applies at every dose, including 5mg. The full Mounjaro overview covers the complete side-effect picture, and the MHRA's Yellow Card scheme is there for patients to report anything unexpected.

Patients at 5mg who use oral contraceptives are advised to add a non-oral method of contraception (condoms, for example) for four weeks after starting this dose and for four weeks after any subsequent dose increase. This is because tirzepatide slows gastric emptying, which can reduce how much of an oral pill is absorbed. Your prescriber will cover this at consultation.

Who is likely to be at the 5mg dose, and what comes next

Most people reach 5mg after spending around four weeks at the 2.5mg starter pen. The 2.5mg pen's job is adjustment, not active treatment, it settles the system before the dose that begins to work on weight in earnest. Some people stay at 5mg longer than four weeks if tolerability is still being established; others move up on the standard schedule. That call rests entirely with the prescriber.

Private eligibility for Mounjaro in the UK covers adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition, high blood pressure, type 2 diabetes, high cholesterol, obstructive sleep apnoea and cardiovascular disease all qualify. Lower thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone is never the whole picture; a prescriber weighs the full clinical context before approving any dose.

If you are wondering about the cost of staying on treatment as doses increase, the context around Eli Lilly's 2025 UK pricing changes is worth reading before you plan ahead, particularly if you are timing a start around payday or the end of the month.

The 5mg dose in the context of weight-loss outcomes is explored in more depth if you want to go further into what the evidence suggests at this stage specifically.

Getting to 5mg through a clinically supervised route

Mounjaro is a prescription-only medicine. The only legal route to it in the UK is a prescription issued after clinical assessment, not a purchase, not a direct order. At nume, that assessment is done by a GPhC-registered Independent Prescriber who reads your consultation the same day. There is no algorithm making the call.

The process is straightforward: free consultation, same-day clinical review, photo-ID and live weight verification, then (if clinically suitable) same-day dispatch via DPD, arriving the next working day in plain packaging. Every repeat order goes through the same clinical check, and if you want to understand how dosing is structured across the full programme, our page on how Mounjaro weight loss injection dosing works is a useful reference before you begin. The consultation page is where to start; our clinical team can answer anything that comes up along the way.

If you still have questions about the wider treatment journey, our FAQs cover the most common ones. And if you are still deciding between treatment options, you can read about what to expect from the Mounjaro 5mg injection specifically alongside the weight-loss treatments overview that lays out what is available and how they compare.